The severe acute respiratory distress syndrome coronavirus-2 (SARS-CoV-2) Omicron variant (B.1.1.529) is spreading rapidly, even in vaccinated individuals, raising concerns about immune escape. Here, we studied neutralizing antibodies and T-cell responses targeting SARS-CoV-2 D614G (wildtype, WT), and the B.1.351 (Beta), B.1.617.2 (Delta), and B.1.1.529 (Omicron) variants of concern (VOC) in a cohort of 60 health care workers after immunization with ChAdOx-1 S, Ad26.COV2.S, mRNA-1273 or BNT162b2. High binding antibody levels against WT SARS-CoV-2 spike (S) were detected 28 days after vaccination with both mRNA vaccines (mRNA-1273 or BNT162b2), which significantly decreased after 6 months. In contrast, antibody levels were lower after Ad26.COV2.S vaccination but did not wane. Neutralization assays with infectious virus showed consistent cross-neutralization of the Beta and Delta variants, but neutralization of Omicron was significantly lower or absent (up to a 34-fold decrease compared to WT). Notably, BNT162b2 booster vaccination after either two mRNA-1273 immunizations or Ad26.COV.2 priming partially restored neutralization of the Omicron variant, but responses were still up to-17-fold decreased compared to WT. SARS-CoV-2-specific T-cells were detected up to 6 months after all vaccination regimens, with more consistent detection of specific CD4+ than CD8+ T-cells. No significant differences were detected between WT- and variant-specific CD4+ or CD8+ T-cell responses, including Omicron, indicating minimal escape at the T-cell level. This study shows that vaccinated individuals retain T-cell immunity to the SARS-CoV-2 Omicron variant, potentially balancing the lack of neutralizing antibodies in preventing or limiting severe COVID-19. Booster vaccinations are needed to further restore Omicron cross-neutralization by antibodies. Description Vaccination-induced SARS-CoV-2-specific CD4+ and CD8+ T-cells targeting the ancestral Spike protein cross-recognize the Omicron variant.
【초록키워드】 neutralizing antibody, antibodies, SARS-CoV-2, vaccination, severe COVID-19, spike, antibody, mRNA vaccine, VoC, B.1.351, mRNA-1273, neutralization, T-cell Response, T-cells, variant, variants of concern, Delta, B.1.617.2, omicron, immunization, variants, BNT162b2, Protein, Cohort, Ad26.COV2.S, Immune escape, response, cross-neutralization, Health care worker, Beta, B.1.1.529, T-cell, T-cell immunity, booster vaccination, acute respiratory distress, Coronavirus-2, Infectious virus, binding antibody, significant difference, syndrome, regimens, CD4+, priming, wildtype, vaccinated individuals, description, CD8+, vaccinated individual, significantly lower, WT SARS-CoV-2, SARS-CoV-2 D614G, responses, decrease, lack, significantly, restored, CD8+ T-cell, raising, the SARS-CoV-2, 【제목키워드】 SARS CoV-2, COVID-19 vaccine, B cell response, recipient,